AOD-9604 for Weight Loss
Research, mechanism, dosing, and effectiveness of AOD-9604 for weight loss.
Quick Answer
AOD-9604 targets fat specifically and can support weight loss programs without affecting blood sugar.
Evidence Level
Human Trials
Typical Dose
250-500 mcg fasted
Results Timeline
Weight loss support over 8-12 weeks
FDA Status
Research Only
How AOD-9604 Works for Weight Loss
Increases fat oxidation and prevents lipogenesis without GH's diabetogenic effects.
About Weight Loss
Reduction of body fat and overall body weight through appetite control and metabolic enhancement.
Research Evidence
Clinical trials showed modest weight loss effects but failed to meet primary endpoints for FDA approval. Some studies show cartilage regeneration potential. Research demonstrates safety profile similar to placebo with no significant GH-like side effects.
Dosing for Weight Loss
Recommended Dose
250-500 mcg fasted
Frequency
Once daily, usually morning fasted
Administration
Subcutaneous injection or oral (studied both)
Duration
12-24 weeks in studies
Note: HGH fragment for fat loss. Take on empty stomach. Often combined with fasted cardio for enhanced fat burning.
What to Expect
Initial adjustment period. Some users may notice subtle changes.
Early benefits often become noticeable. Continue consistent use.
Most users report meaningful improvements by this point.
Full effects typically realized. Reassess and adjust as needed.
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Generally very well-tolerated
- •Injection site reactions
- •Mild headache
- •Dizziness
- •Does NOT produce typical HGH side effects
- •No effect on IGF-1 levels
Frequently Asked Questions
Does AOD-9604 help with weight loss?
AOD-9604 targets fat specifically and can support weight loss programs without affecting blood sugar.
How does AOD-9604 work for weight loss?
Increases fat oxidation and prevents lipogenesis without GH's diabetogenic effects....
What dose of AOD-9604 should I use for weight loss?
250-500 mcg fasted
How long until I see results?
Weight loss support over 8-12 weeks
Other Peptides for Weight Loss
These peptides are also researched for weight loss.
Semaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Tirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Retatrutide
Clinical TrialsA triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
Orforglipron
Clinical TrialsAn oral non-peptide GLP-1 receptor agonist. NDA submitted to FDA with Priority Review. Expected approval by mid-2026.
Educational Information Only
This information about AOD-9604 for weight loss is for educational purposes only. Always consult with qualified healthcare providers before using any peptide. Individual results may vary.